According to CNBC, Geoffrey Kendrick, Head of Digital Asset Research at Standard Chartered Bank, has revised his Bitcoin price forecast, admitting that the previously set target price of $120,000 for the second quarter "may be too low." This analyst accurately predicted the Bitcoin rally for 2024 last year. Kendrick stated that recent market dynamics indicate that institutional funds are continuously flowing into the Bitcoin market through various channels. Over the past three weeks, the net inflow of U.S. spot Bitcoin ETFs reached $5.3 billion. He specifically mentioned several key signals: MicroStrategy's continued accumulation of Bitcoin, Abu Dhabi's sovereign wealth fund holding BlackRock's Bitcoin ETF, and the Swiss National Bank investing in MicroStrategy stock. Kendrick maintains his year-end target price of $200,000, believing that the upward trend may continue through the summer. He pointed out that the market drivers for Bitcoin have shifted from "risk asset correlation" to "capital flow dominance," a structural change that provides greater upside potential for the price.
Standard Chartered Analyst Admits Previous Prediction of Bitcoin Reaching $120,000 in Q2 "May Be Too Low"
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Forex Today: US flash Consumer Sentiment and Canadian jobs in the limelight
Malaysian Ringgit: Fiscal anchor case – MUFG
Nasdaq Drops Over 300 Points After OpenAI's Revenue Comes In $20 Billion Short
BUZZ-Revolution Medicines stock drops due to concerns over pancreatic cancer drug data
On October 8, Revolution Medicines (RVMD.O) shares fell 8.1% in afternoon trading to $185.91. RBC Capital Markets stated that the share price decline appeared to be driven by the latest U.S. Food and Drug Administration (FDA) review documents regarding the company's pancreatic cancer drug Rasonque, particularly the disclosure of objective response rate data for specific RAS mutation subgroups. RBC pointed out that overall survival, rather than objective response rate, is a more meaningful indicator of efficacy, and that the sell-off overlooked Rasonque's broad activity across a variety of RAS mutation subgroups. RBC stated: "While we acknowledge that today's share price decline takes place against the backdrop of overall weakness in the biotech sector, we still believe that the market's reaction to the FDA review documents is an overreaction, given that the drug was approved on the basis of highly clinically meaningful efficacy and has received positive feedback from physicians." Including intraday fluctuations, the stock has more than doubled year-to-date. (Note: For the convenience of non-English speakers, Reuters has automatically translated its reports into several other languages. Automated translations may be inaccurate or lack necessary context; Reuters does not guarantee the accuracy of these automated translations and provides them only for reader convenience. Reuters does not accept liability for any damage or loss arising from the use of automated translation features.)
Crypto prices
More
